Hope for a better tomorrow™

Welcome to TRICCAR

Our Story

Why We Do This

When a family member falls ill to a deadly disease, your perspective on life changes. When the medical community doesn’t have answers, you seek your own solutions.  

Such is the story of TRICCAR Holdings, Inc.  Bill Townsend, President & CEO of TRICCAR, Inc. began his investigations into plant-based medicines for treatment of common diseases and ailments after his sister-in-law, Cynthia, was diagnosed with ALS (Lou Gehrig’s Disease).  
Three years into the disease, having exhausted all medically approved options, including the drug riluzole, Eastern medicine, and stem cell transplants, Cynthia was motionless, confined to a wheelchair, could not speak, and had difficulty swallowing. Even simple things like resting or getting a family member’s attention became impossible. Her discomfort from being mentally awake but trapped in a body that no longer responded to her commands resulted in her sleeping approximately 1 hour each night, causing additional health issues.  

Based on research we conducted, Cynthia began a daily treatment of  1 capsule nightly of TRICCAR Formula #30. Within one week of beginning treatment, Cynthia’s sleep improved from 1 hour to 8 hours each night, appetite increased, and swallowing became easier.  

Three months into treatment she regained much of her swallowing capabilities which delayed the need for a feeding tube. Her pain levels decreased from 6-8 (on a scale of 1 to 10 with 10 representing the most severe pain) to 0-1. She is able to move her hand in order to communicate via phone and computer, and, because of her ability to sleep through the night, her mood improved, she became healthier looking.

Today, Cynthia’s sleep cycle is a consistent 6-8 hours a night plus a 1-2 hour nap in the afternoon and she feels “less fearful” of the debilitating and terminal disease that is ALS.  

The benefits of TRICCAR’s formula, along with its cost-effective price point, led Mr. Townsend to begin investigating other natural solutions to the world’s most common diseases.  

Realizing there were dozens, if not hundres, of researchers around the world conducting important investigative studies on nature’s ability to heal, he began recruiting those interested in forging a new path to healthcare—a path that would put patients first, not patents. A path that would put patients ahead of profits. A path that would scour the ends of the earth seeking treatments to the world’s most severe diseases and ailments, including ALS, diabetic nerve pain, trigeminal neuralgia, cancer, obesity, hypothyroidism, hypothyroidism, cognitive decline and ADHD. A path that would incorporate double-blind and clinical studies to prove the effectiveness of nutraceutical supplements and pharmaceutical solutions with one goal in mind: providing hope for a better tomorrow.   

What We Do

TRICCAR Holdings, Inc. is a for-profit corporation focused on pharmaceutical research and product development targeting the world’s most devastating diseases and ailments: cancer, obesity, hypothyroidism, ALS (Lou Gehrig’s disease), trigeminal neuralgia, diabetic nerve pain,  PTSD, cognitive enhancement, ADHD, calcium deficiencies, and others.  

TRICCAR has developed proprietary investigational approaches to disease treatment and abatement. The average success rate for a pharmaceutical company (disease identification-to- product) is 9.6%.2 TRICCAR’s initial 28 months of R&D led to a November 2016 breakthrough in pre-formulation hypothesis-based design and manufacturing procedures that significantly increased success rates from 16.4% to 47.2. Another advancement increased success rates to 68.4%. This proprietary approach speeds hypothesis-to-testing times, leading to rapid prototyping, and shorter time to double-blind and/or clinical testing and thus, increased speed to market and ROI.

TRICCAR’s business model features a dual-approach that includes nutraceuticals (dietary supplements not requiring Food & Drug Administration approval) and FDA-approved pharmaceuticals. Research, development and initial double-blind studies and/or securitizing rights to solutions that have a cumulative $70 million in research, development, and clinical studies have been completed.    


Whether developing a nutraceutical or a pharmaceutical drug, TRICCAR’s formulae must pass rigorous quality, safety and efficacy trials including double-blind and/or clinical studies.    

Our hypothesis-driven approach to disease abatement includes  alternatives to toxic procedures and drugs that have been shown to kill tissue, cause organ damage, weaken immunity, or otherwise produce side effects that are sometimes worse than the diseases they treat.   


TRICCAR’s product pipeline of over two dozen treatments and solutions addresses obesity and organ fat reduction, hypothyroidism, congenital toxoplasmosis, cognitive enhancement, ADHD, diabetic nerve pain, cancer, non-melanoma skin cancer, Chronic Traumatic Encephalopathy, and general wellness support.   


TRICCAR’s research into cannabinoids (CBD) holds promise in supporting the human and animal endocannabinoid systems. The Company currently has 14 formulae based on naturally occurring plant cannabinoids, including plant species that are legal to grow and cultivate in most countries, including the United States, and a proprietary breed of plants which TRICCAR has developed.    


The Company earmarks 10% of profits to our two non-profit entities that provide low-cost supplements to financially disadvantaged patients and ecological support for governments, NGOs, and universities to facilitate reclamation of distressed habitats and teach sound cultivation practices that protect the environment for future generations, providing hope for a better tomorrow.

A Look Ahead

OFF™ : Possibly the first weight loss nutraceutical that requires no change in diet or exercise in order to remove stubborn organ fat. Taken first thing in the morning with at least 6 ounces of water, double-blind results show an average weight loss of 23.2 pounds in 90 days with a 97% success rate. Very  effective with patients suffering from obesity or those seeking long-lasting weight loss.

 

HTH™ : 12% of the global population will suffer from hypothyroidism during their lifetimes. TRICCAR’s hypothyroidism support nutraceutical has been shown that with a minimum use of 90 days, hypothyroid sufferers experience the following results: 81% of subjects experience a reduction in pain, 79% increased energy, 68% get relief from constipation, 52% obtain relief from sensitivity to cold, 66% report improved sexual performance, and 39% experienced weight loss.


AGE™ : A cognitive improvement formula made from a proprietary blend of five plant extracts. Testing to date on subjects aged 45-78 shows an average self-reported increase in memory and cognition of 67% after 90 days use. TRICCAR is planning a large scale double-blind study to validate these results.   


FCS™ : Created as an offshoot of our memory formula, TRICCAR's FCS formula is designed for students, ages 12-25, to enhance focus for studies or for athletics seeking mental sharpness. Independent analysis of the product and of competent and reliable scientific evidence supports the following:  

a) Improves and boosts energy,  

b) Improves alertness, focus, and concentration,  

c) Supports the formation of short-term memory and the consolidation of long-term memory, sustains mitochondrial biogenesis and neuroprotection,  

d) Supports brain health, cholinergic tone and neurotransmission, human cognitive functioning, plus the formation of short-term memory, and the consolidation of long-term memory,  

e) Supports the ability to create new memories and retrieve memories, and  

f) Supports the ability to learn, recall information, focus attention on attention-demanding tasks, reason, problem solving, and safely supports cognitive functioning.


BLD™ : This blood enhancement formula aids in red blood cells separating: allowing white blood cells freedom of movement and increased ability to destroy harmful bacteria.

  

Future solutions: TRICCAR has conducted limited testing on a trigeminal neuralgia formula. For those suffering from this dreadful disease--often called the Suicide Disease because of its ranking as the most painful disease known to mankind--Formula #51 shows promise in being the only treatment for TN1 and TN2 that provides long-term relief from this nerve disease.


Our approach to diabetic nerve pain is equally exciting with our formula showing promise in treating the common symptoms of diabetes.  Diabetic neuropathy can cause numbness or tingling in your fingers, toes, hands, and feet. Another symptom is a burning, sharp, or aching pain (diabetic nerve pain).  Popular treatments include Lyrica,  Gabarone, Neurontin,  Carbatrol, Tegretol, or anti-depressants.  Formula #54 appears to greatly eliminate numbness, tingling, and pain. Full scale clinical studies are being planned.


We have increased to six the number of formulae that may be utilized to treat multiple cancers. The Company plans to begin clinical trials after its cultivation facility is fully operational and consistent extraction of key ingredients is possible. These pharmaceutical solutions may require FDA approval before being made available to the public. 



  



Subscribe

Sign up to receive updates, news, and more.

Disclaimer

  All statements and expressions are the sole opinion of the editor and are subject to change without notice.  The Company is not liable for any investment decisions by its readers or subscribers.  It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies.  The information contained herein has been provided as an information service only.  The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained.  Investors are cautioned that they may lose all or a portion of their investment in this or any other company.   Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements".  Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.   

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
 

The statements made within the pages of this website are those of the author and should not be taken to mean that any product discussed herein has been proven to be effective for any claims stated herein.   

TRICCAR Holdings, Inc. is a privately-held corporation. All inquiries should be addressed to legal @ triccar . com.      

Wishing you good health.